Skip to Content
Home > Services > Cancer > Clinical Research Trials > Clinical Trial Search > Detail
Back to Results
Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant solid tumors.
Estimate the maximum tolerated dose (MTD) and/or a biologically active dose (eg, recommended phase 2 dose [RP2D]) within investigated subject population groups.
Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12Cmutation identified through DNA sequencing.
Active brain metastases from non-brain tumors.
-- History or presence of hematological malignancies unless curatively treated with no evidence of disease
Kenneth A. Kuenzli II, RN864firstname.lastname@example.org
Thank you for your feedback!
Get the latest news on the health topics that matter most to you.
© 2019 Spartanburg Regional Healthcare System. All Rights Reserved.